Adaptive Biotechnologies Bolsa (NASDAQ: ADPT)

Últimas noticias sobre Adaptive Biotechnologies (NASDAQ:ADPT) Bolsa

Adaptive Biotechnologies

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Adeptus Health

Movers_Stocks

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ADPT

CXAI

ENTO

HRTG

IIIN

LION

LSAK

MLNK

MULN

OLMA

RNAC

SGMO

SHCO

SLSR

Sangamo Therapeutics se dispara tras anunciar un acuerdo exclusivo con Eli Lilly sobre tecnología genética patentada. ¿Qué implica esto?

Acciones de Sangamo Therapeutics (SGMO) se disparan un 40%; Aquí están 20 acciones que se mueven en premercado

Equities

Tech

ETFs

ARKG

ARKK

CDNA

PLTR

VCYT

Ark Invest sorprende con grandes movimientos en Palantir y Tempus AI. Descubre el impacto de estas decisiones clave.

Cathie Wood apuesta 12,2M$ en Tempus AI (TEM) mientras reduce exposición a Palantir (PLTR)

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies Corp

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Overweight and raises the price target from $11 to $13.

Price Target

Analyst Ratings

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $13

5 analysts have expressed a variety of opinions on Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Adaptive Biotechnologies, presenting an average target of $10.2, a high estimate of $12.00, and a low estimate of $9.00. This current average has increased by 24.39% from the previous average price target of $8.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1746475217_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adaptive Biotechnologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tejas Savant</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$9.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$10.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Adaptive Biotechnologies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Adaptive Biotechnologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Adaptive Biotechnologies's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/ADPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptive Biotechnologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Unveiling the Story Behind Adaptive Biotechnologies</h2>
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
<h3>Financial Insights: Adaptive Biotechnologies</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Adaptive Biotechnologies showcased positive performance, achieving a revenue growth rate of 25.24% as of 31 March, 2025. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Adaptive Biotechnologies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -56.92%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Adaptive Biotechnologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.19%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Adaptive Biotechnologies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -5.68%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.46.
<h2>What Are Analyst Ratings?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Adaptive Biotechnologies: What You Need To Know

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Equal-Weight and raises the price target from $7 to $9.

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $9

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite surging more than 300 points on Friday.
The Dow traded up 1.43% to 41,337.37 while the NASDAQ climbed 1.76% to 18,023.33. The S&amp;P 500 also rose, gaining, 1.61% to 5,694.47.
Check This Out: <a href="https://www.benzinga.com/25/05/45164497/jim-cramer-this-financial-stock-is-a-buy-likes-exlservice-holdings">Jim Cramer: Sunrun Had &#8216;Bad Couple Of Quarters,&#8217; ExlService Holdings Is &#8216;Solid&#8217;</a>
Leading and Lagging Sectors Communication services shares jumped by 2.7% on Friday.
In trading on Friday, consumer staples stocks rose by just 0.6%.
Top Headline
Shares of Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell around 4% on Friday after the company reported results for its fiscal second quarter.
The company posted quarterly revenue of $95.36 billion, beating analyst estimates of $94.53 billion. The Cupertino-based company reported second-quarter earnings of $1.65 per share, beating analyst estimates of $1.63 per share.
The company&#8217;s CEO Tim Cook said that the tech giant expects a $900 million cost impact in the June quarter due to tariffs.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Polyrizon Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) shares shot up 295% to $1.0002. The company recently reported successful safety study of a formulation of PL-14 allergy blocker in human nasal tissue model.</li>
<li>Shares of Freight Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRGT#NASDAQ">FRGT</a>)got a boost, surging 111% to $2.0808 on continued strength after the company on Thursday announced it entered into an agreement for the issuance of convertible notes through a facility of up to $20 million. Capital from the financing will be earmarked for purchasing Official Trump Tokens.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares were also up, gaining 36% to $10.02 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) shares dropped 34% to $0.1289 after the company announced a $1.5 million public offering.</li>
<li>Shares of Cable One, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CABO#NYSE">CABO</a>) were down 42% to $152.23 after the company reported worse-than-expected first-quarter financial results. Additionally, Keybanc downgraded the stock from Overweight to Sector Weight.</li>
<li>Draganfly Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) was down, falling 35% to $1.9050 after the company priced a $3.6 million underwritten public offering at $2.10 per unit</li>
</ul>
Commodities In commodity news, oil traded down 1.5% to $58.38 while gold traded up 0.4% at $3,234.20.
Silver traded down 1% to $32.150 on Friday, while copper rose 1.2% to $4.6825.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 1.67%, Spain's IBEX 35 Index gained 1.2% while London's FTSE 100 rose 1.17%. Germany's DAX 40 rose 2.62% and France's CAC 40 added 2.33% during the session.
Asia Pacific Markets
Asian markets closed higher on Friday, with Japan's Nikkei gaining 1.04%, Hong Kong's Hang Seng Index surging 1.74% and India's BSE Sensex rising 0.32%.
Economics
<ul>
<li>Nonfarm payrolls increased by 177,000 last month, slightly down from a downwardly revised 185,000 in March, according to data released Friday by the Bureau of Labor Statistics. The outcome surpassed both economist forecasts for a 130,000 gain and betting markets – tracked by CFTC-regulated platform Kalshi – which had priced in a 90,000 increase.</li>
<li>The unemployment rate remained unchanged at 4.2%, as expected.</li>
<li>New order for U.S. manufactured goods rose by 4.3% to $618.8 billion in March.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a> </li>
</ul>
Photo via Shutterstock

Earnings

Eurozone

Commodities

Intraday Update

AAPL

CABO

DPRO

FRGT

PAPL

PLRZ

Nasdaq Surges Over 300 Points; Apple Shares Fall After Q2 Results

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock moved upwards by 228.7% to $0.83 during Friday's regular session. The company's market cap stands at $33.1 million. </li>
<li>Impact BioMedical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IBO#AMEX">IBO</a>) stock moved upwards by 73.84% to $0.7. The company's market cap stands at $7.9 million. </li>
<li>BioVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIVI#NASDAQ">BIVI</a>) shares moved upwards by 47.32% to $1.27. The market value of their outstanding shares is at $23.4 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares increased by 33.41% to $9.82. The market value of their outstanding shares is at $1.4 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) shares increased by 31.79% to $2.98. The market value of their outstanding shares is at $174.4 million. As per the press release, Q1 earnings came out today. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) shares rose 25.22% to $0.42. The company's market cap stands at $4.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Pro-Dex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDEX#NASDAQ">PDEX</a>) stock fell 35.0% to $43.75 during Friday's regular session. The company's market cap stands at $142.6 million. As per the press release, Q3 earnings came out yesterday. </li>
<li>Ardelyx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARDX#NASDAQ">ARDX</a>) shares decreased by 22.95% to $4.21. The market value of their outstanding shares is at $1.0 billion. As per the news, the Q1 earnings report came out yesterday. </li>
<li>Select Medical Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SEM#NYSE">SEM</a>) stock decreased by 21.0% to $14.41. The company's market cap stands at $1.8 billion. The company's, Q1 earnings came out yesterday. </li>
<li>Regencell Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) shares declined by 19.49% to $62.0. The market value of their outstanding shares is at $806.7 million. </li>
<li>ENDRA Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDRA#NASDAQ">NDRA</a>) shares decreased by 15.28% to $6.1. The company's market cap stands at $3.2 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock declined by 15.19% to $0.23. The company's market cap stands at $10.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ARDX

BIVI

HCTI

NDRA

PDEX

RSLS

12 Health Care Stocks Moving In Friday's Intraday Session

Goldman Sachs analyst Salveen Richter maintains Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) with a Buy and raises the price target from $9 to $10.

Goldman Sachs Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $10

U.S. stocks were higher, with the Dow Jones index gaining around 400 points on Friday.
Shares of Trupanion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRUP#NASDAQ">TRUP</a>) rose sharply during Friday's session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/quote/TRUP/earnings">raised its FY25 sales guidance</a>.
Trupanion reported quarterly loss of 3 cents per share which beat the analyst consensus estimate of loss of 5 cents per share. The company reported quarterly sales of $341.98 million which beat the analyst consensus estimate of $337.82 million.
Trupanion shares jumped 18.2% to $43.08 on Friday.
Here are some other big stocks recording gains in today&#8217;s session.
<ul>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares surged 30% to $9.60 after the company reported first-quarter financial results and beat its EPS and revenue estimates.</li>
<li>NPK International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NPKI#NASDAQ">NPKI</a>) gained 26.6% to $7.65 after the company reported better-than-expected first-quarter financial results.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) rose 23.1% to $4.42.</li>
<li>Highest Performances Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPH#NASDAQ">HPH</a>) gained 23.1% to $7.20.</li>
<li>Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) rose 20.8% to $10.37.</li>
<li>AST SpaceMobile, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTS#NASDAQ">ASTS</a>) climbed 17.4% to $26.96.</li>
<li>iRhythm Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IRTC#NASDAQ">IRTC</a>) rose 17.4% to $127.43 after the company reported better-than-expected first-quarter results and raised its FY25 sales guidance</li>
<li>Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) gained 15% to $460.50 after the company reported better-than-expected first-quarter financial results and raised its FY25 sales guidance.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) gained 13.7% to $79.87 following strong quarterly sales.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) jumped 12.4% to $7.74.</li>
<li>Maplebear Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CART#NASDAQ">CART</a>) gained 11.3% to $44.33 following first-quarter results.</li>
<li>Exact Sciences Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) gained 11.1% to $52.40 after the company reported better-than-expected first-quarter sales results and raised its FY25 sales guidance.</li>
<li>Archer Aviation Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACHR#NYSE">ACHR</a>) gained 10.6% to $9.39.</li>
<li>MasTec, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTZ#NYSE">MTZ</a>) gained 6.4% to $142.68 following first-quarter results.</li>
<li>Robinhood Markets, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) rose 6.3% to $49.58.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45164963/how-to-earn-500-a-month-from-tyson-foods-stock-ahead-of-q2-earnings">How To Earn $500 A Month From Tyson Foods Stock Ahead Of Q2 Earnings</a></li>
</ul>

ACHR

ASTS

CART

DUOL

DXCM

EXAS

HOOD

IRTC

NPKI

PONY

TRUP

WOLF

Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday

WIIM

Adaptive Biotechnologies shares are trading higher after the company reported Q1 financial results and beat its EPS and revenue estimates.

Adaptive Biotechnologies shares are trading higher after the company reported better-than-expected Q1 financial results.

Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.31) by 35.48 percent. This is a 39.39 percent increase over losses of $(0.33) per share from the same period last year. The company reported quarterly sales of $52.40 million which beat the analyst consensus estimate of $42.68 million by 22.77 percent. This is a 25.14 percent increase over sales of $41.87 million the same period last year.

Earnings Beats

Adaptive Biotechnologies Q1 EPS $(0.20) Beats $(0.31) Estimate, Sales $52.40M Beat $42.68M Estimate

AAMI

ABNB

ACCO

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CARR

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

ECVT

ELME

Earnings Scheduled For May 1, 2025

On Wednesday, Cathie Wood-led Ark Invest increased its exposure to NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) and Advanced Micro Devices Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>). These trades come amid ongoing challenges in the semiconductor industry, particularly with U.S. sanctions affecting chip sales to China.
The Nvidia Trade saw Ark Invest&#8217;s ARK Autonomous Technology &amp; Robotics ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>) acquiring 4,731 shares of NVIDIA. The stock closed at $102.71, marking a 3.86% increase from the previous day. The total value of this trade amounted to approximately $485,921.This purchase reflects Ark&#8217;s confidence in NVIDIA&#8217;s potential, even as Chinese tech giants like Alibaba and Tencent <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions">stockpile NVIDIA&#8217;s AI chips</a> due to U.S. sanctions. These chips, specifically the H20 models, were designed to meet U.S. regulatory requirements, yet the looming threat of shipment restrictions has led to a surge in demand from Chinese companies.
The AMD Trade involved Ark&#8217;s ARKQ ETF purchasing 1,808 shares of Advanced Micro Devices. AMD&#8217;s stock saw a 4.79% rise, closing at $90.39. This acquisition, valued at around $163,425, comes as Ark continues to bolster its position in the semiconductor sector. On Tuesday, Ark had <a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus">scooped up AMD shares</a> worth $2.14 million while picking Nvidia stock worth $1.09 million. Both these companies face U.S. export restrictions targeting China.
Other Key Trades:
<ul>
<li>Sold 182 Microsoft (MSFT) shares through ARKW</li>
<li>Sold 40,015 shares of UiPath Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) from ARKF ETF and 8,273 shares through ARKW.</li>
<li>Bought 104,048 shares of Nurix Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) through ARKG.</li>
<li>Sold 147,820 shares of Adaptive Biotechnologies Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) in ARKG ETF.</li>
<li>Purchased 80,661 shares of 10X Genomics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) via ARKG ETF.</li>
</ul>
Benzinga Edge Stock Rankings show AMD has a Momentum in the 12th percentile and Growth in the 66th percentile. Wondering how Nvidia is placed? <a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus">Click here</a> for the full picture.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus"><img loading="lazy" decoding="async" width="792" height="107" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09.png" alt="" class="wp-image-885449" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09.png 792w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09-300x41.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/23211526/Screenshot-2025-04-24-at-10.15.09-768x104.png 768w" sizes="(max-width: 792px) 100vw, 792px" /></a></figure>
Photo Courtesy: T. Schneider on Shutterstock.com
Read Next: <a href="https://benzinga.com/25/04/44942774/elon-musk-slams-tesla-protesters-says-they-benefited-from-government-waste-and-fraud-he-believes-to-have-cut-via-" target="_blank" rel="noreferrer noopener">​</a>
<ul>
<li><a href="https://benzinga.com/25/04/44942774/elon-musk-slams-tesla-protesters-says-they-benefited-from-government-waste-and-fraud-he-believes-to-have-cut-via-" target="_blank" rel="noreferrer noopener">Elon Musk Hits Out At Tesla Protesters, Says They Profited From Government &#8216;Waste And Fraud&#8217; He Cut Using DOGE: &#8216;They&#8217;re The Recipients Of Wasteful Largesse​&#8217;</a></li>
</ul>
This story was generated using <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a> and edited by <a href="https://www.benzinga.com/author/shivdeep-dhaliwal" target="_blank" rel="noreferrer noopener">Shivdeep Dhaliwal</a>

ARKQ

NRIX

NVDA

PATH

Cathie Wood Buys More NVIDIA And AMD Stock As Chinese Tech Giants Stockpile Chips Amid Looming US Export Curbs

Shares of Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) rose sharply in today's pre-market trading as the company reported better-than-expected first-quarter financial results and issued strong <a href="https://in.benzinga.com/news/buybacks/25/04/44911715/calix-stock-jumps-on-strong-q1-earnings-100-million-buyback-increase">second-quarter guidance</a>.
After market close on Monday, cloud and managed services company Calix announced that its board increased its buyback authorization by an additional $100 million, bringing the total repurchase authorization up to $162.9 million.
Calix reported first-quarter revenue of $220.24 million, beating analyst estimates of $206.98 million. The company reported first-quarter adjusted earnings of 19 cents per share, beating estimates of 13 cents per share, according to Benzinga Pro.
Calix shares jumped 13.1% to $37.61 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Gelteq Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) rose 329% to $3.97 in pre-market trading.</li>
<li>Standard Lithium Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLI#NYSE">SLI</a>) surged 44.2% to $2.02 in pre-market trading. Smackover Lithium&#8217;s South West Arkansas Project has received a special designation as a priority transparency critical mineral project from the Trump Administration.</li>
<li>SUNation Energy Inc.  (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNE#NASDAQ">SUNE</a>) gained 36.2% to $3.80 in pre-market after dipping 30% on Monday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) surged 25.3% to $1.09 in pre-market trading after dipping over 22% on Monday.</li>
<li>MicroCloud Hologram Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) gained 25% to $15.25 in pre-market trading after falling around 20% on Monday.</li>
<li>IT Tech Packaging, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITP#NYSE">ITP</a>) jumped 22.4% to $0.2880 in pre-market trading after dipping 11% on Monday.</li>
<li>Meiwu Technology Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WNW#NASDAQ">WNW</a>) rose 21.8% to $1.51 in pre-market trading r after the company announced it regained Nasdaq compliance.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) rose 17.4% to $3.98 in pre-market trading.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) gained 17% to $7.99 in pre-market trading. Adaptive Biotechnologies will report financial results for the first quarter after market close on Thursday, May 1.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>MKDWELL Tech Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MKDW#NASDAQ">MKDW</a>) fell 43.5% to $0.22 in pre-market trading after jumping over 70% on Monday.</li>
<li>TNL Mediagene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNMG#NASDAQ">TNMG</a>) fell 36.7% to $0.1857 in pre-market trading after declining 5% on Monday.</li>
<li>SHF Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHFS#NASDAQ">SHFS</a>) shares fell 22.2% to $3.26 in pre-market trading after jumping around 96% on Monday.</li>
<li>Outset Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares tumbled 16.8% to $8.30 in pre-market trading. Outset Medical will release financial results for the first quarter after the close of trading on Wednesday, May 7.</li>
<li>National Energy Services Reunited Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NESR#NASDAQ">NESR</a>) shares fell 16.4% to $5.00 in pre-market trading.</li>
<li>INmune Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INMB#NASDAQ">INMB</a>) fell 16.1% to $6.11 in pre-market trading.</li>
<li>Gulf Resources, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GURE#NASDAQ">GURE</a>) shares dipped 11.7% to $0.6890 in pre-market trading after dipping over 17% on Monday.</li>
<li>USA Rare Earth, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USAR#NASDAQ">USAR</a>) declined 9.3% to $10.65 in pre-market trading. USA Rare Earth will release financial results for the first quarter, after the closing bell on Wednesday, May 14.</li>
<li>Tyra Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TYRA#NASDAQ">TYRA</a>) fell 7.3% to $8.40 in today's pre-market trading.</li>
<li>SITE Centers Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SITC#NYSE">SITC</a>) dipped 5.7% to $11.01 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44896269/how-to-earn-500-a-month-from-3m-stock-ahead-of-q1-earnings">How To Earn $500 A Month From 3M Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

CALX

GELS

GURE

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMB

MKDW

NESR

SHF Holdings, Inc. - Class A Common Stock

SHFS

SITC

SUNE

TNMG

TYRA

USAR

Why Calix Shares Are Trading Higher By 13%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>icad (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ICAD#NASDAQ">ICAD</a>) shares increased by 72.0% to $3.32 during Wednesday's pre-market session. The company's market cap stands at $87.4 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock increased by 17.82% to $3.9. The market value of their outstanding shares is at $59.3 million. </li>
<li>Renovaro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENB#NASDAQ">RENB</a>) stock rose 12.39% to $0.42. The market value of their outstanding shares is at $66.6 million. </li>
<li>Assembly Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASMB#NASDAQ">ASMB</a>) shares increased by 10.09% to $10.8. The market value of their outstanding shares is at $81.0 million. </li>
<li>Mira Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MIRA#NASDAQ">MIRA</a>) shares moved upwards by 9.06% to $0.98. The company's market cap stands at $16.2 million. </li>
<li>China SXT Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SXTC#NASDAQ">SXTC</a>) stock rose 8.81% to $1.85. The company's market cap stands at $25.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Forian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FORA#NASDAQ">FORA</a>) stock declined by 61.1% to $0.81 during Wednesday's pre-market session. The company's market cap stands at $25.2 million. </li>
<li>BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) shares declined by 15.13% to $1.74. The company's market cap stands at $7.9 million. </li>
<li>Syra Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRA#NASDAQ">SYRA</a>) stock decreased by 14.56% to $0.17. The market value of their outstanding shares is at $2.0 million. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) stock fell 13.44% to $6.7. The company's market cap stands at $988.7 million. </li>
<li>Century Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPSC#NASDAQ">IPSC</a>) stock decreased by 11.18% to $0.45. The market value of their outstanding shares is at $38.2 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares declined by 11.03% to $0.96. The market value of their outstanding shares is at $6.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ASMB

BCDA

FORA

ICAD

IPSC

MIRA

RENB

SXTC

SYRA

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Adaptive Biotechnologies shares are trading higher after the company announced that Palmetto GBA expanded its coverage of cloneSEQ.

Health Care

General

Adaptive Biotechnologies Announces That Palmetto GBA, A Medicare Administrative Contractor Expanded Coverage Of clonoSEQ

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,200 points on Friday.
Shares of Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) fell sharply in today's pre-market trading after the company reported <a href="https://www.benzinga.com/quote/ges">fourth-quarter financial results.</a>
Guess? reported upbeat results for its fourth quarter and named Alberto Toni as CFO. The company said it sees FY26 revenue to increase 3.9% – 6.2% in US Dollars and adjusted EPS of $1.32 – $1.76.
Guess shares dipped 3% to $9.74 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>MeridianLink, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) shares tumbled 20.5% to $13.99 in pre-market trading after falling 4% on Thursday.</li>
<li>Newsmax, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NMAX#NYSE">NMAX</a>) shares fell 19.2% to $50.18 in pre-market trading after gaining 18% on Thursday.</li>
<li>Stevanato Group S.p.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) shares dipped 18.8% to $16.30 in pre-market trading.</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) shares fell 18.3% to $20.11 in pre-market trading. Insteel Industries will announce its second quarter 2025 earnings on Thursday, April 17.</li>
<li>Global Industrial Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) declined 17.3% to $18.00 in today's pre-market trading after dipping 5% in Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) dipped 16.7% to $6.16 in pre-market trading after dipping 7% on Thursday.</li>
<li>Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) shares dipped 16.1% to $13.11 in pre-market trading.</li>
<li>Mizuho Financial Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MFG#NYSE">MFG</a>) shares fell 14.3% to $4.25 in pre-market trading.</li>
<li>Deutsche Bank Aktiengesellschaft (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DB#NYSE">DB</a>) dipped 11.5% to $20.25 in pre-market trading.</li>
<li>Barclays PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BCS#NYSE">BCS</a>) shares fell 11.5% to $12.67 in pre-market trading  after dipping 9% on Thursday.</li>
<li>Alibaba Group Holding Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) declined 9.3% to $117.30 in pre-market trading.</li>
<li>JD.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) dipped 8.8% to $36.41 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 4.8% to $254.40 in pre-market trading. Tesla shares fell over 5% on Thursday after the company reported weaker-than-expected performance for the first quarter of 2025.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) fell 3.8% to $97.98 in pre-market trading after dipping around 8% on Thursday.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a></li>
</ul>
Photo via Shutterstock

BABA

NMAX

STVN

TSLA

Guess, Tesla, Nvidia And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Shares of Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) rose sharply in today's pre-market trading after the company announced a new agreement with pharmaceutical giant Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), granting the company a worldwide exclusive license to leverage the company&#8217;s novel proprietary neurotropic adeno-associated virus (AAV) <a href="https://www.benzinga.com/quote/sgmo">capsid, STAC-BBB.</a>
Sangamo Therapeutics shares jumped 39.5% to $0.8684 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Impact BioMedical Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IBO#NYSE">IBO</a>) gained 115.3% to $0.9990 in pre-market trading after falling around 19% on Thursday.</li>
<li>Mullen Automotive, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MULN#NASDAQ">MULN</a>) rose 82% to $0.1447 in pre-market trading after dipping over 22% on Thursday.</li>
<li>Wellchange Holdings Company Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCT#NASDAQ">WCT</a>) rose 69.4% to $0.3303 in pre-market trading after jumping 23% on Thursday.</li>
<li>Olema Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLMA#NASDAQ">OLMA</a>) rose 49.3% to $5.00 in pre-market trading.</li>
<li>Entero Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTO#NASDAQ">ENTO</a>) gained 40.1% to $0.6123 in pre-market after gaining 6% on Thursday.</li>
<li>CXApp Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CXAI#NASDAQ">CXAI</a>) surged 37.6% to $1.11 in pre-market trading after the company reported business performance results for 2024 and announced a net revenue retention rate of 101%.</li>
<li>Soho House &amp; Co Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHCO#NYSE">SHCO</a>) gained 20% to $7.09 in pre-market trading following a 5% decline on Thursday.</li>
<li>Lionsgate Studios Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LION#NASDAQ">LION</a>) gained 11.1% to $7.90 in pre-market trading after falling 6% on Thursday.</li>
<li>Compass Minerals International, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMP#NYSE">CMP</a>) rose 4.5% to $9.61 in pre-market trading.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Lesaka Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSAK#NASDAQ">LSAK</a>) fell 57.8% to $2.00 in pre-market trading.</li>
<li>Sangamo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) shares fell 48.7% to $6.31 in pre-market trading following a 5% decline on Thursday.</li>
<li>Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) declined 38.3% to $2.01 in pre-market trading.</li>
<li>Greenfire Resources Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GFR#NYSE">GFR</a>) fell 22.6% to $4.21 in pre-market trading after dipping 9% on Thursday.</li>
<li>MeridianLink, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) dipped 20.5% to $13.99 in pre-market trading after falling 4% on Thursday.</li>
<li>Insteel Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIIN#NYSE">IIIN</a>) shares tumbled 18.3% to $20.11 in pre-market trading. Insteel Industries will announce its second quarter 2025 earnings on Thursday, April 17.</li>
<li>Global Industrial Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIC#NYSE">GIC</a>) fell 17.3% to $18.00 in today's pre-market trading after dipping 5% in Thursday.</li>
<li>Adaptive Biotechnologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) fell 16.7% to $6.16 in pre-market trading after dipping 7% on Thursday.</li>
<li>Heritage Insurance Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRTG#NYSE">HRTG</a>) shares dipped 16.1% to $13.11 in pre-market trading.</li>
<li>Emerald Holding, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EEX#NYSE">EEX</a>) shares fell 15.7% to $3.21 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44641655/guess-simulations-plus-and-3-stocks-to-watch-heading-into-friday">Guess, Simulations Plus And 3 Stocks To Watch Heading Into Friday</a> </li>
</ul>
Photo via Shutterstock

Why Sangamo Therapeutics Shares Are Trading Higher By Around 40%; Here Are 20 Stocks Moving Premarket

<h3>Gainers</h3>
<ul>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock moved upwards by 151.6% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $4.1 million. As per the press release, Q4 earnings came out 2 days ago. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock rose 32.6% to $1.83. The company's market cap stands at $2.6 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) shares moved upwards by 32.16% to $0.39. The company's market cap stands at $3.3 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock rose 12.66% to $0.23. The company's market cap stands at $6.1 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Oragenics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/OGEN#AMEX">OGEN</a>) stock rose 10.2% to $0.22. The market value of their outstanding shares is at $4.7 million. </li>
<li>Biodesix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDSX#NASDAQ">BDSX</a>) stock moved upwards by 9.92% to $0.69. The market value of their outstanding shares is at $100.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) stock declined by 21.1% to $0.7 during Wednesday's after-market session. The market value of their outstanding shares is at $10.9 million. As per the news, the Q4 earnings report came out 2 days ago. </li>
<li>Twist Bioscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) shares declined by 16.27% to $32.0. The company's market cap stands at $1.9 billion. </li>
<li>Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) shares decreased by 13.73% to $6.85. The company's market cap stands at $1.0 billion. </li>
<li>Cerus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CERS#NASDAQ">CERS</a>) stock decreased by 12.86% to $1.22. The company's market cap stands at $226.6 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) shares decreased by 12.08% to $0.7. The market value of their outstanding shares is at $50.3 million. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares fell 11.04% to $1.37. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

BDRX

BDSX

BIAF

CTOR

GNPX

KLTO

OGEN

PTIX

TWST

12 Health Care Stocks Moving In Wednesday's After-Market Session

Analysts' ratings for Adaptive Biotechnologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $9.88, along with a high estimate of $12.00 and a low estimate of $7.50. Marking an increase of 29.66%, the current average surpasses the previous average price target of $7.62. 
<img src="https://www.benzinga.com/files/images/story/2025/1742583625_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Adaptive Biotechnologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$9.00</td>
<td>$8.00</td>
</tr>
<tr>
<td>David Westenberg</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$11.00</td>
<td>$7.00</td>
</tr>
<tr>
<td>Sung Ji Nam</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Outperform</td>
<td>$12.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Neutral</td>
<td>$7.50</td>
<td>$5.50</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Adaptive Biotechnologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Adaptive Biotechnologies compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Adaptive Biotechnologies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/ADPT/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Adaptive Biotechnologies analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Discovering Adaptive Biotechnologies: A Closer Look</h2>
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).
<h3>Breaking Down Adaptive Biotechnologies's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Adaptive Biotechnologies displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 3.66%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: Adaptive Biotechnologies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -70.99%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Adaptive Biotechnologies's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -15.8%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Adaptive Biotechnologies's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.14%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Adaptive Biotechnologies's debt-to-equity ratio is below the industry average. With a ratio of 0.44, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>What Are Analyst Ratings?</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Expectations For Adaptive Biotechnologies's Future

Press Releases

Adaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025

Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients

Small Cap

Cutting-Edge Cancer Therapies Lead the Way into a Transformative Year

Comments

Adaptive Biotechnologies

Noticias

Últimas noticias sobre Adaptive Biotechnologies (NASDAQ:ADPT) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL